| 来源类型 | Working Paper |
| 规范类型 | 报告 |
| DOI | 10.3386/w10007 |
| 来源ID | Working Paper 10007 |
| Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand | |
| Patricia M. Danzon; Jonathan D. Ketcham | |
| 发表日期 | 2003-10-06 |
| 出版年 | 2003 |
| 语种 | 英语 |
| 摘要 | This paper describes three prototypical systems of therapeutic reference pricing (RP) for pharmaceuticals -- Germany, the Netherlands, and New Zealand -- and examines their effects on the availability of new drugs, reimbursement levels, manufacturer prices and out-of-pocket surcharges to patients. RP for pharmaceuticals is not simply analogous to a defined contribution approach to subsidizing insurance coverage. Although a major purpose of RP is to stimulate competition, theory suggests that this is unlikely and this is confirmed by the empirical evidence. Other effects of RP differ across countries in predictable ways, reflecting each country's system design and other cost control policies. New Zealand's RP system has reduced reimbursement and limited the availability of new drugs, particularly more expensive drugs. Compared to these three countries, if RP were applied in the US, it would likely have a more negative effect on prices of on-patent products, due to the more competitive US generic market, and a more negative effect on R&D and on the future supply of new drugs, due to the much larger US share of global pharmaceutical sales. |
| 主题 | Health, Education, and Welfare ; Health |
| URL | https://www.nber.org/papers/w10007 |
| 来源智库 | National Bureau of Economic Research (United States) |
| 引用统计 | |
| 资源类型 | 智库出版物 |
| 条目标识符 | http://119.78.100.153/handle/2XGU8XDN/567631 |
| 推荐引用方式 GB/T 7714 | Patricia M. Danzon,Jonathan D. Ketcham. Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand. 2003. |
| 条目包含的文件 | ||||||
| 文件名称/大小 | 资源类型 | 版本类型 | 开放类型 | 使用许可 | ||
| w10007.pdf（393KB） | 智库出版物 | 限制开放 | CC BY-NC-SA | 浏览 | ||
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。
